These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3827680)

  • 1. Prediction of early beneficial response to plasma exchange in Guillain-Barré syndrome.
    Gruener G; Bosch EP; Strauss RG; Klugman M; Kimura J
    Arch Neurol; 1987 Mar; 44(3):295-8. PubMed ID: 3827680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasmapheresis versus plasma perfusion in acute Guillain-Barré syndrome.
    Morosetti M; Meloni C; Taccone Gallucci M; Rossini PM; Felicioni R; Palombo G; Boccasena P; Casciani CU
    ASAIO J; 1994; 40(3):M638-42. PubMed ID: 8555592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Motor conduction studies in Guillain-Barré syndrome: description and prognostic value.
    Cornblath DR; Mellits ED; Griffin JW; McKhann GM; Albers JW; Miller RG; Feasby TE; Quaskey SA
    Ann Neurol; 1988 Apr; 23(4):354-9. PubMed ID: 3382170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasmapheresis in the treatment of the Guillain-Barré syndrome in childhood.
    Yoshioka M; Kuroki S; Mizue H
    Pediatr Neurol; 1985; 1(6):329-34. PubMed ID: 2854736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe Guillain-Barré syndrome in aged patients: the effect of plasmapheresis.
    Yamashita S; Morinaga T; Matsumoto K; Sakamoto T; Kaku N; Matsukura S
    Intern Med; 1992 Nov; 31(11):1313-6. PubMed ID: 1295631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrophysiologic studies in the Guillain-Barré syndrome: effects of plasma exchange and antibody rebound.
    Rudnicki S; Vriesendorp F; Koski CL; Mayer RF
    Muscle Nerve; 1992 Jan; 15(1):57-62. PubMed ID: 1732763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus infection and Guillain-Barré syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barré Study Group.
    Visser LH; van der Meché FG; Meulstee J; Rothbarth PP; Jacobs BC; Schmitz PI; van Doorn PA
    Neurology; 1996 Sep; 47(3):668-73. PubMed ID: 8797462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.
    Hadden RD; Cornblath DR; Hughes RA; Zielasek J; Hartung HP; Toyka KV; Swan AV
    Ann Neurol; 1998 Nov; 44(5):780-8. PubMed ID: 9818934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of therapeutic plasmapheresis in the acute Guillain-Barré syndrome.
    McKhann GM; Griffin JW; Cornblath DR; Quaskey SA; Mellits ED
    J Neuroimmunol; 1988 Dec; 20(2-3):297-300. PubMed ID: 3198752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guillain-Barré syndrome: clinical and therapeutic observations.
    McKhann GM
    Ann Neurol; 1990; 27 Suppl():S13-6. PubMed ID: 2194419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motor nerve inexcitability in Guillain-Barré syndrome. The spectrum of distal conduction block and axonal degeneration.
    Triggs WJ; Cros D; Gominak SC; Zuniga G; Beric A; Shahani BT; Ropper AH; Roongta SM
    Brain; 1992 Oct; 115 ( Pt 5)():1291-302. PubMed ID: 1422789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute "axonal" Guillain-Barré syndrome in childhood.
    Reisin RC; Cersósimo R; García Alvarez M; Massaro M; Fejerman N
    Muscle Nerve; 1993 Dec; 16(12):1310-6. PubMed ID: 8232386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. There are no neurophysiologic features characteristic of "axonal" Guillain-Barré syndrome.
    Cros D; Triggs WJ
    Muscle Nerve; 1994 Jun; 17(6):675-7. PubMed ID: 8196711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Guillain-Barré syndrome with nerve conduction blocks at multiple common entrapment sites that rapidly disappeared after plasmapheresis].
    Susuki K; Johkura K; Kawauchi Y; Hasegawa O; Kuroiwa Y
    Rinsho Shinkeigaku; 1998 Mar; 38(3):270-2. PubMed ID: 9711129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of Guillain-Barré syndrome with "axonal" involvement by plasma exchange].
    Mezaki T; Kaji R; Kimura J; Shibasaki H
    Rinsho Shinkeigaku; 1992 Oct; 32(10):1140-2. PubMed ID: 1297561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Guillain-Barré syndrome and plasma exchange].
    Raphael JC; Elkharrat D; Chevret S; Vercken JB; Chastang C; Gajdos P
    Ann Med Interne (Paris); 1990; 141(7):593-6. PubMed ID: 2085236
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barré Study Group.
    Visser LH; Schmitz PI; Meulstee J; van Doorn PA; van der Meché FG
    Neurology; 1999 Aug; 53(3):598-604. PubMed ID: 10449126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome in severe pediatric Guillain-Barré syndrome after immunotherapy or supportive care.
    Graf WD; Katz JS; Eder DN; Smith AJ; Chun MR
    Neurology; 1999 Apr; 52(7):1494-7. PubMed ID: 10227643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical and neurophysiologic study of Guillain Barré syndrome: results of therapy with plasmapheresis].
    Fasanaro AM; Pizza V; Florio C; Tancredi G; Fabbri P; Aiello L; Viscidi E; Rossi V; Vacca C
    Riv Neurol; 1991; 61(1):39-45. PubMed ID: 1857922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome.
    Bril V; Ilse WK; Pearce R; Dhanani A; Sutton D; Kong K
    Neurology; 1996 Jan; 46(1):100-3. PubMed ID: 8559353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.